Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management.

@article{Rossi2014AntitumourNF,
  title={Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management.},
  author={Roberta Elisa Rossi and Ioanna Parisi and Edward J Despott and Andrew K. Burroughs and James O'Beirne and Dario Conte and Mark Ian Hamilton and Charles D R Murray},
  journal={World journal of gastroenterology},
  year={2014},
  volume={20 46},
  pages={
          17352-9
        }
}
Abnormalities in liver function tests, including transient and self-limiting hypertransaminasemia, cholestatic disease and hepatitis, can develop during treatment with anti-tumour-necrosis-factor (TNF) therapy. The optimal management of liver injury related to anti-TNF therapy is still a matter of debate. Although some authors recommend discontinuing treatment in case of both a rise of alanine aminotransferase more than 5 times the upper limit of normal, or the occurrence of jaundice, there are… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 81 REFERENCES

Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases.

  • Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2013

Tumor necrosis factor inhibitors for inflammatory bowel disease

S Bezabeh, CM Flowers, C Kortepeter, M Avigan
  • N Engl J Med
  • 2013

[A case of infliximab-related liver damage -case report and literature review].

  • Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • 2013

Adali - mumab in prevention of postoperative recurrence of Crohn ’ s disease in high - risk patients

K Yoshida, K Fukunaga, +12 authors H Miwa
  • World J Gastroenterol
  • 2012